首页 | 本学科首页   官方微博 | 高级检索  
     


Distributional Cost-Effectiveness Analysis of Health Technologies: Data Requirements and Challenges
Affiliation:1. PHMR Limited, London, England, UK;2. Evidence for Access, Genentech, Inc, South San Francisco, CA, USA;3. Global Access, F. Hoffmann-La Roche Ltd, Grenzacherstrasse, Basel, Switzerland;4. National Institute for Health and Care Excellence, Manchester, England, UK;5. Centre for Health Economics, University of York, York, England, UK;1. Health Economics Unit, School of Population and Global Health, The University of Melbourne, Melbourne, Australia;2. National Perinatal Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, England, UK;1. Division of Research and Technology, Isfahan University of Medical Sciences, Isfahan, Iran;2. Department of Computer Science, University of Saskatchewan, Saskatchewan, Canada;3. Alliance Manchester Business School, The University of Manchester, Manchester, England, UK;4. Department of Information and Industrial Engineering, Yonsei University, Seoul, South Korea;1. National Health Council, Washington, DC, USA;2. Merck & Co, Inc, Rahway, NJ, USA;3. Celiac Disease Foundation, Woodland Hills, CA, USA;4. Innovation and Value Initiative, Alexandria, VA, USA;5. Genesis Research, Hoboken, NJ, USA;6. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Lawrenceville, NJ, USA;7. Department of Pharmaceutical Health Services Research, University of Maryland Baltimore, Baltimore, MD, USA;1. National Health Council, Washington, DC, USA;2. Applied Patient Experience, LLC, Washington, DC, USA;3. Merck & Co., Inc., Rahway, NJ, USA;4. University of Arkansas for Medical Sciences, Little Rock, AR, USA;1. Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA;2. Harvard Medical School, Boston, MA, USA;3. Division of Cardiology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA;4. Medtronic, Inc, Minneapolis, MN, USA;1. Lumanity, Sheffield, England, UK;2. School of Health and Related Research, University of Sheffield, Sheffield, England, UK;3. Centre for Health Economics, University of York, York, England, UK;4. The National Institute for Health and Care Excellence, London, England, UK;5. Department of Health Sciences, University of York, York, England, UK
Abstract:Governments and health technology assessment agencies are putting greater focus on and efforts in understanding and addressing health inequities. Cost-effectiveness analyses are used to evaluate the costs and health gains of different interventions to inform the decision-making process on funding of new treatments. Distributional cost-effectiveness analysis (DCEA) is an extension of cost-effectiveness analysis that quantifies the equity impact of funding new treatments. Key challenges for the routine and consistent implementation of DCEA are the lack of clearly defined equity concerns from decision makers and endorsed measures to define equity subgroups and the availability of evidence that allows analysis of differences in data inputs associated with the equity characteristics of interest. In this article, we detail the data gaps and challenges to build robust DCEA analysis routinely in health technology assessment and suggest actions to overcome these hurdles.
Keywords:distributional cost-effectiveness analysis  equity  health inequities
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号